Famciclovir

Source: Wikipedia, the free encyclopedia.
Famciclovir
Clinical data
Pronunciation/ˌfæmˈsaɪkloʊˌvɪər/[1]
Trade namesFamvir
AHFS/Drugs.comMonograph
MedlinePlusa694038
Pregnancy
category
  • AU: B1
By mouth
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability75–77%
Protein binding20–25%
MetabolismLiver, circulation, intestinal wall (to penciclovir)
Elimination half-life2–2.3 hours
ExcretionKidney, faecal
Identifiers
  • 2-[(acetyloxy)methyl]-4-(2-amino-9H-purin-9-yl)butyl acetate
JSmol)
Melting point103 °C (217 °F)
  • O=C(OCC(COC(=O)C)CCn1c2nc(ncc2nc1)N)C
  • InChI=1S/C14H19N5O4/c1-9(20)22-6-11(7-23-10(2)21)3-4-19-8-17-12-5-16-14(15)18-13(12)19/h5,8,11H,3-4,6-7H2,1-2H3,(H2,15,16,18) checkY
  • Key:GGXKWVWZWMLJEH-UHFFFAOYSA-N checkY
  (verify)

Famciclovir is a

herpes zoster (shingles). It is a prodrug form of penciclovir with improved oral bioavailability. Famciclovir is marketed under the trade name Famvir (Novartis
).

Famciclovir was patented in 1983 and approved for medical use in 1994.

Mylan Pharmaceuticals.[5][6]

Medical uses

Famciclovir is indicated for the treatment of herpes zoster (shingles),[7] treatment of herpes simplex virus 2 (genital herpes),[8] herpes labialis (cold sores) in immunocompetent patients[9] and for the suppression of recurring episodes of herpes simplex virus 2. It is also indicated for treatment of recurrent episodes of herpes simplex in HIV patients.[citation needed]

Adverse effects

Side effects: mild to extreme stomach upset, headaches, mild fever.

Herpes

Early treatment

Several studies in humans and mice provide evidence that early treatment with famciclovir soon after the first infection with herpes can significantly lower the chance of future outbreaks. Use of famciclovir in this manner has been shown to reduce the amount of latent virus in the neural ganglia compared to no treatment or treatment with valaciclovir.[10][11][12] A review of human subjects treated for five days with famciclovir 250 mg three times daily during their first herpes episode found that only 4.2 percent experienced a recurrence within six months after the first outbreak, a fivefold decrease compared to the 19 percent recurrence in acyclovir-treated patients.[13] Neither drug affected latency if treatment was delayed for several months.[14]

References

  1. ^ "Famciclovir". Merriam-Webster.com Dictionary. Retrieved 2016-01-22.
  2. ^ "Prescription medicines: registration of new generic medicines and biosimilar medicines, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 30 March 2024.
  3. ISBN 978-1437727029
    .
  4. ISBN 9783527607495
    .
  5. better source needed
    ]
  6. ^ "Mylan Launches Generic Version of Famvir® Tablets" (Press release). Mylan. 20 April 2011. Archived from the original on July 23, 2011. Retrieved 21 April 2011.
  7. S2CID 35498460
    .
  8. S2CID 27057728
    .
  9. PMID 16781291
    .
  10. PMID 10993926
    .
  11. PMID 9660982
    .
  12. PMID 10602729
    .
  13. ^ "Observation May Indicate A Possible Clinical Effect On Latency". Doctor's Guide Publishing Limited. Archived from the original on 2012-02-16.
  14. PMID 8568288
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Famciclovir&oldid=1216818882"